SELLAS Life Sciences Group Inc. (SLS) Short-Term Debt to Capital

This daily price chart for SELLAS Life Sciences (SLS) shows the current value at 0.01. The business relies on participant retention within current studies while awaiting FDA approval to commence sales. The management model is based on outsourcing synthesis and testing to contractors, retaining only the intellectual property. Development is focused on creating peptide drugs to combat leukemia.

SELLAS Life Sciences focuses on developing highly scalable immunotherapeutic drugs to combat oncology. The calculation model compares the volume of liabilities due within one year against the amount of equity, identifying critical liquidity gaps. This ratio determines the company's ability to service short-term loans without compromising financial stability. By analyzing the dynamics of the short-term debt-to-equity ratio, an investor can assess the risks of cash shortages while preparing for mass production.